Propensity score adjusted analysis of patients with isolated locoregional recurrence versus de novo locally advanced NSCLC treated with definitive therapy.
Sign Up to like & getrecommendations! Published in 2020 at "Lung cancer"
DOI: 10.1016/j.lungcan.2020.04.035
Abstract: OBJECTIVES Definitive intent treatment of isolated locoregional recurrence (iLR) for non-small cell lung cancer (NSCLC) is becoming more common. This study explores outcomes associated with the definitive local treatment of iLR and compares these outcomes… read more here.
Keywords: nsclc; locoregional recurrence; therapy; nsclc treated ... See more keywords
Induction chemotherapy backbone in frail patients with advanced NSCLC treated with chemotherapy plus pembrolizumab: a single institution retrospective audit of dose intensities from modified regimens.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Chemotherapy"
DOI: 10.1080/1120009x.2024.2388474
Abstract: Abstract Guidelines historically recommended mono-chemotherapy for the 1st line treatment of elderly patients with non-small cell lung cancer (NSCLC) and poor performance status (PS). Nowadays, there is no clear indication whether chemo-immunotherapy (chemo-IO) combinations can… read more here.
Keywords: modified regimens; induction chemotherapy; chemotherapy; plus pembrolizumab ... See more keywords
Baseline and changes in inflammatory parameters for patients with EGFR ‐mutated NSCLC treated with afatinib
Sign Up to like & getrecommendations! Published in 2025 at "Thoracic Cancer"
DOI: 10.1111/1759-7714.15338
Abstract: This study investigated the relationship between inflammatory biomarkers (lymphocyte ratio [NLR], monocyte‐to‐lymphocyte ratio [MLR], and platelet‐to‐lymphocyte ratio [PLR]) and the treatment outcomes of patients with non‐small cell lung cancer (NSCLC) treated with afatinib. read more here.
Keywords: inflammatory parameters; treated afatinib; baseline changes; changes inflammatory ... See more keywords
Prognostic factors for survival in NSCLC treated with immunotherapy: An institutional analysis.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.e20591
Abstract: e20591 Background: Immune check point inhibitors (ICIs) are the cornerstone of treatment for patients with advanced NSCLC. However, not all patients benefit from ICIs and some develop significant immune-mediated toxicities. There is limited data regarding… read more here.
Keywords: treated icis; factors survival; analysis; count ... See more keywords